PharmaCyte Biotech Introduces Cell-in-a-Box as a Novel Treatment for Pancreatic Cancer and Potential Cure for Type 1 Diabetes...
January 19 2016 - 9:25AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, released today another in a series of
educational articles that will serve to educate the public on its
live-cell encapsulation technology and its pancreatic cancer and
diabetes treatments using that technology. This educational piece
titled, Cellular Microencapsulation: Cell Encapsulation for Drug
Delivery & Disease Treatment, is authored by PharmaCyte’s Chief
Operating Officer, Dr. Gerald W. Crabtree.
The article can be read at:
http://www.pharmacyte.com/wp-content/uploads/2016/01/Cellular-Microencapsulation.pdf
In the article Dr. Crabtree introduces
microencapsulation and its role in a disease treatment system. A
number of areas where microencapsulation can be most effective are
discussed, including diabetes, neurological disorders and
pancreatic cancer. The article specifically addresses PharmaCyte’s
live-cell encapsulation technology, Cell-in-a-Box®, and how it can
be a novel treatment alternative for pancreatic cancer and a
potential cure for type 1 diabetes.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage
biotechnology company focused on developing and preparing to
commercialize treatments for cancer and diabetes based upon a
proprietary cellulose-based live cell encapsulation technology
known as “Cell-in-a-Box®.” This unique and patented technology will
be used as a platform upon which treatments for several types of
cancer and diabetes are being developed. PharmaCyte’s
treatment for cancer involves encapsulating genetically modified
live cells that convert an inactive chemotherapy drug (ifosfamide)
into its active or “cancer-killing” form. These encapsulated live
cells are placed as close to a cancerous tumor as possible. Once
implanted in a patient, ifosfamide is then given intravenously at
one-third the normal dose. The ifosfamide is carried by the
circulatory system to where the encapsulated cells have been
placed. When ifosfamide, which is normally activated in the liver,
comes in contact with the encapsulated live cells, activation of
the drug takes place at the source of the cancer without any side
effects from the chemotherapy. This “targeted chemotherapy” has
proven remarkably effective and safe to use in past clinical
trials.
In addition to developing a novel treatment for
cancer, PharmaCyte is developing a treatment for Type 1 diabetes
and Type 2 insulin-dependent diabetes. PharmaCyte plans to
encapsulate a human cell line that has been genetically engineered
to produce, store and release insulin in response to the levels of
blood sugar in the human body. The encapsulation will be done using
the Cell-in-a-Box® technology.
Safe Harbor This press release may
contain forward-looking statements regarding PharmaCyte Biotech and
its future events and results that involve inherent risks and
uncertainties. The words "anticipate," "believe," "estimate,"
"expect," "intend," "plan" and similar expressions, as they relate
to PharmaCyte Biotech or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte Biotech, could cause actual
results to differ materially from those set forth in the
forward-looking statements. They include PharmaCyte's ability to
continue as a going concern, delays or unsuccessful results in
preclinical and clinical trials, flaws or defects regarding its
product candidates, changes in relevant legislation or regulatory
requirements, uncertainty of protection of PharmaCyte Biotech’s
intellectual property and PharmaCyte Biotech’s continued ability to
raise capital. PharmaCyte Biotech does not assume any obligation to
update any of these forward-looking statements. More information
about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can
also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com